X

Trial Profile

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms PFROST

Most Recent Events

09 Sep 2022 Status changed from active, no longer recruiting to completed according to final results of the PFROST Trial presented at the 2022 World Conference on Lung Cancer.
09 Aug 2022 Final results of the PFROST Trial presented at the 2022 World Conference on Lung Cancer
13 Jul 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com